26-A-19859-ACC HS235, A NEXT-GENERATION BMP-9/-10-SPARING ACTIVIN SIGNALING INHIBITOR FOR THE TREATMENT OF PULMONARY HYPERTENSION (PH) AND HEART FAILURE: RESULTS FROM A PHASE 1 HEALTHY VOLUNTEER TRIAL DEMONSTRATING FAVOURABLE SAFETY AND PHARMACODYNAMIC EFFECTS

View at publisher Summarise with VIRAT
Authors: Maureen O’Connor, Julia Schoelermann, Emilie Brule, Claire Viallard, Gauthier Schang, Florian Dilasser, Adam‐Nicolas Pelletier, Sarya Aziz, Guillaume Lemieux, Julie Bédard, Monique Champagne, George Georges
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Fields of Study & Subjects

Pulmonary Hypertension Research and Treatments TGF-β signaling in diseases Cardiac Fibrosis and Remodeling

Publication details

Journal / source
Journal of the American College of Cardiology
Volume
87
Issue
13
Pages
A967–A967
Publication date
27 March 2026
Language
EN